slovenia_3158_600x450.jpgRecently I had the pleasure of presenting at the Euromabnet meeting held September 24-25 in Ljubljana, Slovenia.  Slovenia, formerly part of Yugoslavia is nestled a short drive from Venice on the Adriatic sea and bordered by Croatia, Hungary, Italy and Austria.

The Euromabnet is a consortium of antibody researchers from across Europe including, Croatia, Czech Republic, France, Germany, Hungary, Italy, Netherlands, Russia, Slovia, Spain and Great Britain.  According to their website,, “EuroMAbNet represents the first European network of laboratories linked to academic Institutions, each having an internationally recognized reputation in the production and use of monoclonal antibodies. EuroMAbNet spans eleven European countries and members possess a wealth of expertise in monoclonal antibody technology ranging from identification and production of immunogens, the production of fully validated antibodies and their use as research tools, diagnostic/prognostic reagents and therapeutics.”  There is a need in Europe and beyond for a forum or forums to exchange knowledge in the field of monoclonal antibodies, validation of antibodies and production of antibodies which Euromabnet provides.

The efforts of Euromabnet are complimentary to the Antibody Research Group (ARG) within the Association of Biomolecular Resource Facilities.  I gave a presentation on the ABRF and ARG which has the following goals:

Sharing it’s collective knowledge about generating, producing, purifying, fragmenting and conjugating antibodies amongst it’s members and within the larger scientific community
Providing a mechanism by which protocols, organizational structures and fiscal approaches could collected, shared and compared
Advancing and evaluating the technology within the antibody field (i.e. rabbit monoclonal antibodies, phage display technology)

The 2-day meeting had a mixture of academic and industrial presentations spanning several technology areas including nanobodies (Serge Muyldermans), hybridoma screening technology (Benjamin Hoffstrom ), human antibody technology (Irene Sanjuan Nandin, Myriam Chentouf), Therapeutic antibodies (Demin Li), virology (Vanda Juranić Lisnić), immunology (Pablo Engel) and cell biology (Marta Cañamero, Ayham Alnabulsi, Balogh Péter, Jose Ignacio Rodriguez Barbosa) as well as a talk on licensing antibody intellectual property (Hugh Spotswood).

Their 2016 meeting will be held in Croatia and hosted by Vanda Juranić Lisnić.